Skip to content

Early-phase trial shows promise for refractory CD30-positive lymphoma
ELM-1 cohort study assesses odronextamab after CAR-T therapy for DLBCL
Pathways & Perspectives with Charles Craddock, CBE
Dr. Kidson-Gerber discusses guidelines for pregnant patients with blood cancers
Early-phase study shows promise of novel CAR-T talicabtagene autoleucel for B-cell malignancies

Join SOHO

Follow Us :

Home
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Roundtable Discussions
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Cellular Therapy

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Leukemia

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Lymphoma

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Multiple Myeloma

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Myelodysplastic Syndromes

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

April 17, 2025

Home
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Roundtable Discussions
Subscribe

SOHO Insider Hem/Onc Library Myeloproliferative Neoplasms

MPN News

Rio de Janeiro, Brazil - September 10, 2020: ANVISA, National Health Surveillance Agency, on smartphone screen. In Brazil, it exercises sanitary control over all products and services

Myeloproliferative Neoplasms News Polycythemia Vera

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

by SOHO Insider Editors
March 25, 2025
0 Comments

Myeloproliferative Neoplasms

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

by SOHO Insider Editors
February 28, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

spleen

Myeloproliferative Neoplasms Primary Myelofibrosis

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

by SOHO Insider Editors
January 28, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Do driver mutations influence treatment outcomes in myelofibrosis?

by Leah Sherwood
January 10, 2025
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera

Orphan drug designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

by SOHO Insider Editors
January 6, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

by sohonews
November 8, 2024
0 Comments

US Flag

Myeloproliferative Neoplasms

US veterans face high symptom burden, limited access to care in MPNs

by Leah Sherwood
June 7, 2024
0 Comments

POPULAR NEWS

MyeloMatch, NCI

Acute Myeloid Leukemia , Leukemia , Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

January 3, 2025

Imatinib

66th American Society of Hematology Annual Meeting & Exposition , Leukemia

Asciminib benefit-risk profile bests other TKIs in CML

December 10, 2024

Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Neoplasms , News , Society Updates

Abstract submissions now open for SOHO 2025

February 14, 2025

Top Categories

Cellular Therapy

10

Leukemia

28

Lymphoma

30

Multiple Myeloma

22

Myelodysplastic Syndromes

11

Myeloproliferative Neoplasms

8

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Categories

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Cellular Therapy

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Leukemia

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Lymphoma

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Multiple Myeloma

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Myelodysplastic Syndromes

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Bispecific antibody in action, digital 3d artwork illustration

Early-phase trial shows promise for refractory CD30-positive lymphoma

infusion

ELM-1 cohort study assesses odronextamab after CAR-T therapy for DLBCL

Charles Craddock

Pathways & Perspectives with Charles Craddock, CBE

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.